Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
multi-specific therapeutic
Biotech
AbbVie pays $65M for options on EvolveImmune's T-cell engagers
Days after inking a $1.4 billion buyout, AbbVie has put up the same in biobucks to secure options on multispecific T-cell engagers.
Nick Paul Taylor
Oct 31, 2024 10:00am
Purple snags Immunorizon's tri-specific antibodies in small M&A
Feb 2, 2023 10:20am
Amgen avoids 'low-hanging fruit' in tackling undruggable targets
Jun 29, 2022 3:00pm
Amgen targets 'multi-specifics' in drug development's 4th wave
Nov 4, 2021 11:37am
Vasella helps Numab to CHF22M round ahead of cancer trial start
Mar 9, 2020 7:00am
